Publicaciones en colaboración con investigadores/as de Hospital de Clínicas de Porto Alegre (7)

2024

  1. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    Journal of Hepatology

2023

  1. Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients with Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis

    HemaSphere

  2. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

    Future oncology (London, England), Vol. 19, Núm. 38, pp. 2505-2516

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

    Liver International, Vol. 40, Núm. 6, pp. 1467-1476

2018

  1. Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy

    Breast Cancer Research and Treatment, Vol. 172, Núm. 3, pp. 523-537